UPDATE: Cantor Fitzgerald Initiates Sucampo Pharmaceuticals with Buy Rating on Near-Term Excitement, Long-Term Value

In a report published Wednesday, Cantor Fitzgerald analyst Irina Rivkind initiated coverage on Sucampo Pharmaceuticals

with a Buy rating and $9.00 price target. In the report, Rivkind noted, “Sucampo is a closely held gastroenterology- and ophthalmology-focused company whose key product, Amitiza, has a near-term catalyst in opioid-induced constipation that we believe could significantly rally the stock. We also like the company's Amitiza partnership with Takeda, which we believe could lead to eventual company take-out if future Amitiza cash flows are de-risked via generic settlement in 2015. We have conservative assumptions for newly launched Rescula, a glaucoma drug that targets a niche patient population.” Sucampo Pharmaceuticals closed on Tuesday at $6.33.